The 2026 American Society of Clinical Oncology (ASCO) annual meeting just concluded in Chicago, Illinois. The 2026 ASCO Annual Meeting featured groundbreaking research presentations, networking events, and continuing education opportunities. From May 29 through June 2, attendees experienced sessions that featured global leaders in oncology discussing key developments shaping the future of the field.

Today, we have a curated selection of some of the abstracts presented during the 2026 ASCO Annual Meeting, specifically abstracts focused on multiple myeloma. Visit the 2026 ASCO abstracts archive to view the full versions of the following abstracts, along with the more than 7,200 other abstracts presented at the meeting.

Multiple Myeloma Abstracts from the 2026 ASCO Annual Meeting 

Real-World Comparison of Remission Status in Newly Diagnosed Multiple Myeloma Treated with Daratumumab-Based Versus Bortezomib-Based First-Line Therapy

  • Description: The introduction of CD38 monoclonal antibodies has transformed the frontline management of newly diagnosed multiple myeloma. However, real-world differences in remission status between daratumumab-based and proteasome inhibitor–based first-line regimens remain incompletely characterized outside of clinical trials.
  • Conclusion: In this large real-world analysis of patients with newly diagnosed multiple myeloma, first-line daratumumab-based therapy was associated with a higher prevalence of documented remission compared with bortezomib-based therapy.

Real-World Treatment Patterns and Clinical Characteristics of Patients with T(11;14)-Positive Multiple Myeloma

  • Description: Multiple myeloma patients harboring the t(11;14) translocation represent a distinct subtype with unique biological and clinical characteristics. While t(11;14)+ patients are increasingly being targeted in clinical studies, there is limited data on how they present in the community oncology setting. Here, [the researchers] aimed to characterize renal function and treatment of t(11;14)+ patients using a large, geographically diverse real-world data platform.
  • Conclusion: [The researchers] found a high rate of renal impairment in t(11;14)+ patients at the time of their first multiple myeloma diagnosis and an inverse relationship between regimen intensity and time to adjustment. Together, these results lay a critical foundation for better understanding how t(11;14)+ patients are managed in routine clinical practice.

Real-World Safety of Elranatamab in Low-Weight Patients: Findings from the SUMMIT Study

  • Description: Elranatamab is the first BCMA bispecific antibody approved in Japan for treatment of patients with heavily pre-treated multiple myeloma. Although prior clinical work supports the safety of elranatamab’s fixed dose formulation (Elmeliegy 2025), assessing its tolerability across different patient weights in a real-world context is important, especially in typically lower weight Asian populations. This study aimed to characterize the safety of elranatamab among real-world patients with multiple myeloma by weight in Japan.
  • Conclusion: Safety outcomes and elranatamab administration patterns were comparable for Japanese patients by weight. Further investigation in larger samples of this population is warranted.

Divergence Between Regulatory Approvals and Guideline Recommendations in Multiple Myeloma: Helping Solve Physicians’ Dilemmas with a Real-Time Updated Evidence Library

  • Description: Despite the large number of trials and emergence of new therapies/combinations in multiple myeloma, guidelines highlight uncertainties in ranking all treatment options and providing therapy sequencing recommendations. For therapies for which regulatory assessment is delayed or not pursued, there is additional uncertainty around the availability and quality of the data informing off-label use. [The researchers] aimed to understand the alignment between guideline recommendations and regulatory endorsement in multiple myeloma and assess whether creation of a living evidence library could help address these gaps.
  • Conclusion: There is a pronounced guideline-regulatory divergence despite substantial growth and diversification of evidence in the past years across newly diagnosed and relapsed/refractory MM. Continuously maintained real-time AI-assisted living systematic reviews that reflect disease and treatment pathways can complement guidelines and regulatory documentation, providing a living data support tool to make informed decisions for patient treatment.

Burden of Disease Management Among Patients with Multiple Myeloma and Their Care Partners

  • Description: The complexity of current multiple myeloma treatment regimens imposes burdens on daily life, impacting quality of life for both patients and care partners. This study characterizes the holistic burden with current treatment, including challenges with treatment logistics and perceptions of novel therapies (e.g., bispecific antibody]/chimeric antigen receptor-T).
  • Conclusion: While advances in multiple myeloma treatment improve survival, treatment complexity and side effects remain distinct burdens on patients and care partners. These findings highlight a pressing need for more tolerable and less burdensome therapies, both from physical and socio-economic perspectives, that restore autonomy and quality of life beyond clinical outcomes. Further research will aim to quantify this need.

Cardiovascular Outcomes After Bispecific T-Cell-Engager Therapy in Multiple Myeloma: A Propensity-Matched Real-World Study

  • Description: Bispecific T-cell engager therapies have emerged as highly effective immunotherapeutic agents for relapsed and refractory multiple myeloma by redirecting cytotoxic T-cell activity toward malignant plasma cells. However, immune activation associated with bispecific T-cell engager therapy may lead to systemic inflammation, cytokine release, and off-target effects, potentially increasing cardiovascular complications and healthcare utilization. Real-world evidence describing cardiovascular outcomes and longitudinal healthcare burden in this population remains limited.
  • Conclusion: In this large real-world cohort, bispecific T-cell engager therapy in multiple myeloma was associated with increased healthcare utilization and heart failure exacerbations without a statistically significant increase in mortality or thrombotic events.

Association Between Palliative Care Consultation and End-of-Life Care Intensity in Multiple Myeloma

  • Description: Multiple myeloma is characterized by an unpredictable disease course, repeated lines of therapy, and substantial symptom burden, complicating integration of palliative care. Optimal referral timing for palliative care in multiple myeloma remains poorly defined. [The researchers] evaluated the association between palliative care consultation timing and end-of-life care intensity in patients with multiple myeloma.
  • Conclusion: In multiple myeloma, absence of palliative care consultation or delayed referral is associated with more aggressive end-of-life care. Palliative care consultation occurring 31–90 days before death was associated with lower care intensity, fewer hospitalizations, and longer hospice engagement.

Don't miss out on our other previews and recaps for future conferences. Sign up for alerts and stay informed on the latest published guidelines and articles.